Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Articles tagged with "Certolizumab Pegol"

Ixekizumab Promising for AS; Plus Certolizumab Pegol Studied for Psoriasis

Michele B. Kaufman, PharmD, BCGP  |  March 14, 2018

In a Phase 3 study, ixekizumab proved safe and effective to treat adults with ankylosing spondylitis (AS)…

EU Approves Certolizumab Pegol for Pregnant & Nursing Patients

Michele B. Kaufman, PharmD, BCGP  |  January 23, 2018

In the EU, certolizumab pegol has been approved for use in pregnant and nursing women with chronic rheumatic disease…

High Cost of Rheumatoid Arthritis Medications Burdens Patients in Saudi Arabia

Lina El Kibbi  |  March 20, 2017

In the past 15 years, rheumatoid arthritis (RA) has posed an economic burden on patients in Saudi Arabia due to the high cost of the medications used to treat the condition. As a rheumatology consultant, I’ve observed the economic impact on patients in one clinic in a private hospital in Riyadh. RA is a chronic,…

Certolizumab Pegol Promising for Plaque Psoriasis in Phase 3 Trial

Michele B. Kaufman, PharmD, BCGP  |  March 1, 2017

Certolizumab pegol has proved safe and effective for treating patients with plaque psoriasis in a Phase 3 clinical trial…

Certolizumab Pegol Usage Compatible with Breastfeeding

Michele B. Kaufman, PharmD, BCGP  |  December 20, 2016

In a small-scale study, researchers found that no, or minimal amounts of, certolizumab pegol transfers from mothers taking the drug to nursing infants…

Transfer of Certolizumab in Breast Milk Not a Concern

Reuters Staff  |  November 22, 2016

NEW YORK (Reuters Health)—There is minimal to no transfer of the tumor necrosis factor (TNF) inhibitor certolizumab (Cimzia) from plasma to breast milk, according to a new study. “These findings are reassuring” and imply that continuing certolizumab treatment is compatible with breastfeeding, Dr. Megan Clowse of Duke University School of Medicine in Durham, North Carolina,…

New RA Therapy Promising in Clinical Trial

Michele B. Kaufman, PharmD, BCGP  |  August 3, 2016

Results from a clinical trial support the efficacy of vobarilizumab for treating RA. Plus, the UK will recommend the use of certolizumab pegol to treat severe cases of RA in upcoming guidelines…

Certolizumab Pegol Combination Therapy Better than Methotrexate Monotherapy in DMARD-Naive Patients with RA

Michele B. Kaufman, PharmD, BCGP  |  June 29, 2016

A recent study found that certolizumab pegol plus methotrexate is effective in achieving sustained remission and low disease activity in patients with early active RA…

Certolizumab Combo Helps Curb RA Damage

David Douglas  |  June 15, 2016

NEW YORK (Reuters Health)—Certolizumab pegol (Cimzia, UCB Pharma) in combination with methotrexate does better than methotrexate alone in certain patients with early rheumatoid arthritis (RA), according to one-year results from a new trial. As Dr. Paul Emery of the University of Leeds, UK, explains in an email to Reuters Health, “This study used a unique…

Biologic DMARDs Prove Effective for Psoriatic Arthritis & Combination DMARDs Show Promise for RA

Michele B. Kaufman, PharmD, BCGP  |  December 25, 2015

In clinical trials, ixekizumab and adalimumab proved safe and effective in treating adults with active psoriatic arthritis. Also, the combination therapy of certolizumab pegol plus methotrexate was more effective than placebo for treating severe RA…

  • « Previous Page
  • 1
  • 2
  • 3
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences